Antiviral activity of bone morphogenetic proteins and activins

Autor: Hal Drakesmith, Chia Chi Sun, Diego Martines, Marco Binder, Narayan Ramamurthy, Cynthia Sandor, L A Eddowes, Slobodan Vukicevic, Stephane Chevaliez, Andrew E. Armitage, Jamie Frankish, João Arezes, Jan Rehwinkel, J. Crowe, Jodie L. Babitt, Caleb Webber, Matthew W. Lawless, Eleni Giannoulatou, John Ryan, Hannah T Baddock, Paul Klenerman, Maria Teresa Giordani, Herbert Y. Lin, Dahlene N. Fusco, Peter J. McHugh, Owens Bmj., Paolo Fabris, K Al-Hourani, Raymond T. Chung, S Boninsegna

Understanding the control of viral infections is of broad importance. Chronic hepatitis C virus (HCV) infection causes decreased expression of the iron hormone hepcidin, which is regulated by hepatic bone morphogenetic protein (BMP)/SMAD signalling.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3712a070ea9fbbc58aeacfc182a4dd1
https://doi.org/10.1038/s41564-018-0301-9

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Autor: Gerhard Müller-Newen, Johanna Pott, Dieter Görtz, C Cieluch, Travis Spl., Satish Keshav, Owens Bmj., Frédéric Baribaud, Samuel J. Bullers, Nathan R. West, Carrie Brodmerkel, Anja A. Kühl, S Plevy, K Stockenhuber, Raymond J. Owens, Kevin J. Maloy, Ahmed N. Hegazy, Fiona Powrie, Bryan Linggi, Nahid Rahman, Matthias Friedrich, S This, Grigory Ryzhakov, Sofia Buonocore, Margherita Coccia

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammatory conditions of the gastrointestinal tract that are driven by perturbed cytokine pathways. Anti-tumor necrosis factor-α (TN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f1d943638f5891c64391bae955786e0
https://eprints.gla.ac.uk/198290/1/198290.pdf

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Autor: Johanna Pott, Gerhard Müller-Newen, Matthias Friedrich, Bryan Linggi, Anja A. Kühl, Carrie Brodmerkel, Frédéric Baribaud, S Plevy, Fiona Powrie, Nathan R. West, Nahid Rahman, Ahmed N. Hegazy, Dieter Görtz, Samuel J. Bullers, K Stockenhuber, Raymond J. Owens, Kevin J. Maloy, C Cieluch, Travis Spl., S This, Satish Keshav, Margherita Coccia, Sofia Buonocore, Owens Bmj., Grigory Ryzhakov

Publikováno v: Nature Medicine. 23:788-788

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d83c523a8fc4ae283f7f5deacbd268b
https://doi.org/10.1038/nm0617-788d

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.

Autor: Gritti G; Hematology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy. g.gritti@asst-pg23.it., Raimondi F; Pneumology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Postgraduate School of Respiratory Medicine, University of Milan, Milan, Italy., Bottazzi B; Humanitas Clinical and Research Center - IRCCS, Milan, Italy., Ripamonti D; Infectious Diseases Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Riva I; Intensive Care Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Landi F; Hematology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Postgraduate School of Hematology, University of Milan, Milan, Italy., Alborghetti L; Infectious Diseases Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Frigeni M; Hematology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Damiani M; Intensive Care Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Postgraduate School of Anesthesiology and Intensive Care, University of Milan, Milan, Italy., Micò C; Hematology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Fagiuoli S; Gastroenterology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Lorini FL; Intensive Care Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Gandini L; Intensive Care Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Postgraduate School of Anesthesiology and Intensive Care, University of Milan, Milan, Italy., Novelli L; Pneumology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Morgan JP; EUSA Pharma, Hemel Hempstead, UK., Owens BMJ; EUSA Pharma, Hemel Hempstead, UK., Kanhai KJK; EUSA Pharma, Hemel Hempstead, UK., Reljanovic GT; ErgoMed PLC, Guildford, UK., Rizzi M; Infectious Diseases Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy., Di Marco F; Pneumology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Department of Health Sciences, University of Milan, Milan, Italy., Mantovani A; Postgraduate School of Respiratory Medicine, University of Milan, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; The William Harvey Research Institute, Queen Mary University of London, London, UK., Rambaldi A; Hematology Unit, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Department of Oncology-Hematology, University of Milan, Milan, Italy.

Publikováno v: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2710-2714. Date of Electronic Publication: 2021 May 24.

Antiviral activity of bone morphogenetic proteins and activins.

Autor: Eddowes LA; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Al-Hourani K; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Ramamurthy N; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK., Frankish J; Research Group 'Dynamics of Early Viral Infection and the Innate Antiviral Response', Division Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany., Baddock HT; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Sandor C; Dementia Research Institute, Cardiff University, Cardiff, UK., Ryan JD; Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland.; Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK., Fusco DN; Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Arezes J; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Giannoulatou E; Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Boninsegna S; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.; Department of Surgical Gastroenterological Science, University of Padua, Padova, Italy., Chevaliez S; Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Owens BMJ; Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK., Sun CC; Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Fabris P; Department of Infectious Diseases and Tropical Medicine, San Bortolo Hospital, Vicenza, Italy., Giordani MT; Department of Infectious Diseases and Tropical Medicine, San Bortolo Hospital, Vicenza, Italy., Martines D; Department of Surgical Gastroenterological Science, University of Padua, Padova, Italy., Vukicevic S; Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia., Crowe J; Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland., Lin HY; Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Rehwinkel J; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., McHugh PJ; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Binder M; Research Group 'Dynamics of Early Viral Infection and the Innate Antiviral Response', Division Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany., Babitt JL; Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chung RT; Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lawless MW; Experimental Medicine, UCD School of Medicine and Medical Science, Mater Misericordiae University Hospital, Dublin, Ireland., Armitage AE; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Webber C; Dementia Research Institute, Cardiff University, Cardiff, UK.; Department of Physiology, Anatomy & Genetics, Oxford University, Oxford, UK., Klenerman P; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK.; NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK., Drakesmith H; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK. alexander.drakesmith@imm.ox.ac.uk.; Haematology Theme Oxford Biomedical Research Centre, Oxford, UK. alexander.drakesmith@imm.ox.ac.uk.

Publikováno v: Nature microbiology [Nat Microbiol] 2019 Feb; Vol. 4 (2), pp. 339-351. Date of Electronic Publication: 2018 Dec 03.